The Oxford COVID-19 Vaccine is 'Progressing Very Well'
They intend to inoculate approximately 10,000 people
Friday, the head of the Oxford Vaccine Group, Professor Andrew Pollard, said its clinical trials are "progressing very well" and that the program will inoculate 10,000 new people. The trial vaccine is called AZD1222 or ChAdOx1 nCoV-19. It was first tested on two humans on April 23 in Oxford, following promising results on six macaque monkeys in the U.S. in March.
"We are now initiating studies to evaluate how well the vaccine induces immune responses in older adults," Pollard, head of the Oxford Vaccine Group, said in a press release.
"The clinical studies are progressing very well."
Please select this link to read the complete article from Business Insider.